JP2024503091A5 - - Google Patents

Info

Publication number
JP2024503091A5
JP2024503091A5 JP2023542960A JP2023542960A JP2024503091A5 JP 2024503091 A5 JP2024503091 A5 JP 2024503091A5 JP 2023542960 A JP2023542960 A JP 2023542960A JP 2023542960 A JP2023542960 A JP 2023542960A JP 2024503091 A5 JP2024503091 A5 JP 2024503091A5
Authority
JP
Japan
Prior art keywords
aav vector
seq
nucleic acid
capsid protein
recombinant aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503091A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/012542 external-priority patent/WO2022155482A1/en
Publication of JP2024503091A publication Critical patent/JP2024503091A/ja
Publication of JP2024503091A5 publication Critical patent/JP2024503091A5/ja
Pending legal-status Critical Current

Links

JP2023542960A 2021-01-14 2022-01-14 T細胞を標的とするaavベクター Pending JP2024503091A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163137497P 2021-01-14 2021-01-14
US63/137,497 2021-01-14
PCT/US2022/012542 WO2022155482A1 (en) 2021-01-14 2022-01-14 Aav vectors targeting t-cells

Publications (2)

Publication Number Publication Date
JP2024503091A JP2024503091A (ja) 2024-01-24
JP2024503091A5 true JP2024503091A5 (https=) 2025-01-22

Family

ID=81328090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542960A Pending JP2024503091A (ja) 2021-01-14 2022-01-14 T細胞を標的とするaavベクター

Country Status (10)

Country Link
US (1) US20240123085A1 (https=)
EP (1) EP4277920A1 (https=)
JP (1) JP2024503091A (https=)
KR (1) KR20230135093A (https=)
CN (1) CN117203222A (https=)
AR (1) AR124651A1 (https=)
AU (1) AU2022208037A1 (https=)
CA (1) CA3204794A1 (https=)
TW (1) TW202242124A (https=)
WO (1) WO2022155482A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
WO2024124019A2 (en) * 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
WO2025179007A1 (en) * 2024-02-21 2025-08-28 The Regents Of The University Of California Adeno-associated virus compositions and methods of use thereof for human cells

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7966987A (en) 1986-09-08 1988-04-07 Applied Biotechnology, Inc. Empty viral capsid vaccines
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
EP0442926A1 (en) 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptides
US5916563A (en) 1988-11-14 1999-06-29 United States Of America Parvovirus protein presenting capsids
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ES2026826A6 (es) 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados.
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
ATE354957T1 (de) 1995-12-15 2006-03-15 Intronn Inc Durch trans-spaltung erhaltene therapeutische molekule
US6083702A (en) 1995-12-15 2000-07-04 Intronn Holdings Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
WO1998011244A2 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
WO1999061601A2 (en) 1998-05-28 1999-12-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav5 vector and uses thereof
AU774706B2 (en) 1998-09-22 2004-07-08 Johns Hopkins University, The Methods for large-scale production of recombinant AAV vectors
ATE362542T1 (de) 1998-11-05 2007-06-15 Univ Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
US7314912B1 (en) 1999-06-21 2008-01-01 Medigene Aktiengesellschaft AAv scleroprotein, production and use thereof
US7201898B2 (en) 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
US6623729B2 (en) 2001-07-09 2003-09-23 Korea Advanced Institute Of Science And Technology Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer
AU2003223766A1 (en) 2002-04-30 2003-11-17 University Of North Carolina At Chapel Hill Secretion signal vectors
ITRM20020253A1 (it) 2002-05-08 2003-11-10 Univ Roma Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
JP4346526B2 (ja) 2004-08-31 2009-10-21 株式会社東芝 半導体集積回路装置
CN101056539B (zh) 2004-09-09 2012-12-12 综合医院公司 调节心脏细胞中的磷酸酶活性
JP5136766B2 (ja) 2004-12-15 2013-02-06 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル キメラベクター
WO2006119432A2 (en) * 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
JP2008539698A (ja) 2005-04-29 2008-11-20 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 転写後レベルでの核酸発現調節のための方法および組成物
CA2638913A1 (en) 2006-02-10 2007-09-07 The University Of Cincinnati Phosphatase inhibitor protein-1 as a regulator of cardiac function
CN101711164B (zh) 2007-01-18 2014-06-04 密苏里-哥伦比亚大学 可修复肌纤维膜中的神经元型一氧化氮合酶的合成小/微-抗肌萎缩蛋白基因
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US9938541B2 (en) * 2012-12-25 2018-04-10 Takara Bio Inc. AAV variant
ES2926774T3 (es) 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
EP3003391B1 (en) * 2013-05-31 2021-09-22 The Regents of The University of California Adeno-associated virus variants and methods of use thereof
KR102451510B1 (ko) * 2016-09-08 2022-10-07 2세븐티 바이오, 인코포레이티드 Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
JP2020510424A (ja) * 2017-02-28 2020-04-09 アドヴェラム バイオテクノロジーズ, インコーポレイテッド 改変aavカプシドおよびその使用
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
EP3774852A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Antibody-evading virus vectors
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.

Similar Documents

Publication Publication Date Title
JP2023544683A5 (https=)
JP2024503091A5 (https=)
FI4211231T3 (fi) Peptidimodifioitu aav-kapsidi
JP2024178382A5 (https=)
JP2022527199A5 (https=)
JP2022513308A5 (https=)
JP2023506765A5 (https=)
JP2023179436A5 (https=)
JP2022507454A5 (https=)
JP2021521833A5 (https=)
CN112040988A (zh) 修饰的aav衣壳多肽用于治疗肌肉疾病
JP2020508685A5 (https=)
JP2025184979A5 (https=)
JP2020510428A5 (https=)
JP2010516758A5 (https=)
JP2020518268A5 (https=)
JP2023504773A5 (https=)
JP2023524291A5 (https=)
JP2022513459A5 (https=)
JPWO2020218419A5 (https=)
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
JP2023554379A5 (https=)
JP2024523394A5 (https=)
JP2022512589A5 (https=)
FI4536686T3 (fi) Lihaksen parannetun transduktiotehokkuuden omaava peptidimodifioitu aav-kapsidi